Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: An underappreciated symbiotic relationship

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 152-160

  Dibra, Denada ^a   Mishra, Lopa ^a   Li, Shulin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

K RAS; NF kappaB; Oncogene induced inflammation; P53; STAT3; WNT

Indexed keywords

APC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; BETA CATENIN; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MICRORNA; WNT PROTEIN;

CANCER PREVENTION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; COLITIS; COLORECTAL CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; GASTROINTESTINAL TUMOR; GENE ACTIVATION; GENE DISRUPTION; GENE MUTATION; HEPATITIS; HNF4A GENE; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREATITIS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; CANCER GROWTH; CD8+ T LYMPHOCYTE; DISEASE ASSOCIATION; DOWN REGULATION; GENE INACTIVATION; GENE OVEREXPRESSION; GENETIC STABILITY; IMMUNOLOGICAL TOLERANCE; INTESTINE MUCOSA PERMEABILITY; LIVER CANCER; PANCREAS CANCER; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS; UPREGULATION;

K-RAS; NF-KAPPAB; ONCOGENE-INDUCED INFLAMMATION; P53; STAT3; WNT;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; ONCOGENES; PERMEABILITY; SIGNAL TRANSDUCTION;

EID: 84901642569     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.05.001     Document Type: Review

References (80)

1. Arthur J.C., Perez-Chanona E., Muhlbauer M., Tomkovich S., Uronis J.M., Fan T.J., Campbell B.J., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
2. Hernandez-Vargas H., Lambert M.P., Le Calvez-Kelm F., Gouysse G., McKay-Chopin S., Tavtigian S.V., Scoazec J.Y., et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 2010, 5:e9749.
3. Chen G.Y., Nunez G. Inflammasomes in intestinal inflammation and cancer. Gastroenterology 2011, 141:1986-1999.
4. Ullman T.A., Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140:1807-1816.
5. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
6. Cooks T., Pateras I.S., Tarcic O., Solomon H., Schetter A.J., Wilder S., Lozano G., et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013, 23:634-646.
7. Schwitalla S., Ziegler P.K., Horst D., Becker V., Kerle I., Begus-Nahrmann Y., Lechel A., et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013, 23:93-106.
8. Fearon E.R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 2011, 6:479-507.
9. Brentnall T.A., Crispin D.A., Rabinovitch P.S., Haggitt R.C., Rubin C.E., Stevens A.C., Burmer G.C. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994, 107:369-378.
10. Wernert N., Locherbach C., Wellmann A., Behrens P., Hugel A. Presence of genetic alterations in microdissected stroma of human colon and breast cancers. Anticancer Res. 2001, 21:2259-2264.
11. Grivennikov S.I., Wang K., Mucida D., Stewart C.A., Schnabl B., Jauch D., Taniguchi K., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
12. Liang J., Nagahashi M., Kim E.Y., Harikumar K.B., Yamada A., Huang W.C., Hait N.C., et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 2013, 23:107-120.
13. Snider A.J., Kawamori T., Bradshaw S.G., Orr K.A., Gilkeson G.S., Hannun Y.A., Obeid L.M. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J. 2009, 23:143-152.
14. Kawamori T., Kaneshiro T., Okumura M., Maalouf S., Uflacker A., Bielawski J., Hannun Y.A., et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J. 2009, 23:405-414.
15. Lee H., Deng J., Kujawski M., Yang C., Liu Y., Herrmann A., Kortylewski M., et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med. 2010, 16:1421-1428.
16. Heffernan-Stroud L.A., Helke K.L., Jenkins R.W., De Costa A.M., Hannun Y.A., Obeid L.M. Defining a role for sphingosine kinase 1 in p53-dependent tumors. Oncogene 2012, 31:1166-1175.
17. Kohno M., Momoi M., Oo M.L., Paik J.H., Lee Y.M., Venkataraman K., Ai Y., et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol. Cell. Biol. 2006, 26:7211-7223.
18. Vermeulen L., Morrissey E., van der Heijden M., Nicholson A.M., Sottoriva A., Buczacki S., Kemp R., et al. Defining stem cell dynamics in models of intestinal tumor initiation. Science 2013, 342:995-998.
19. Meira L.B., Bugni J.M., Green S.L., Lee C.W., Pang B., Borenshtein D., Rickman B.H., et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Invest. 2008, 118:2516-2525.
20. Suh Y.A., Post S.M., Elizondo-Fraire A.C., Maccio D.R., Jackson J.G., El-Naggar A.K., Van Pelt C., et al. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 2011, 71:7168-7175.
21. Schwitalla S., Fingerle A.A., Cammareri P., Nebelsiek T., Goktuna S.I., Ziegler P.K., Canli O., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013, 152:25-38.
22. Umar S., Sarkar S., Wang Y., Singh P. Functional cross-talk between β-catenin and NFκB signaling pathways in colonic crypts of mice in response to progastrin. J. Biol. Chem. 2009, 284:22274-22284.
23. Barker N., Van Es J.H., Kuipers J., Kujala P., Van Den Born M., Cozijnsen M., Haegebarth A., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003-1007.
24. Dove W.F., Clipson L., Gould K.A., Luongo C., Marshall D.J., Moser A.R., Newton M.A., et al. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res. 1997, 57:812-814.
25. Uronis J.M., Muhlbauer M., Herfarth H.H., Rubinas T.C., Jones G.S., Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009, 4:e6026.
26. Wu S., Rhee K.J., Albesiano E., Rabizadeh S., Wu X., Yen H.R., Huso D.L., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17T cell responses. Nat. Med. 2009, 15:1016-1022.
27. Seki E., Kondo Y., Iimuro Y., Naka T., Son G., Kishimoto T., Fujimoto J., et al. Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings. J. Hepatol. 2008, 48:237-245.
28. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
29. Marquardt J.U., Raggi C., Andersen J.B., Seo D., Avital I., Geller D., Lee Y.H., et al. Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology 2011, 54:1031-1042.
30. Doi T.S., Marino M.W., Takahashi T., Yoshida T., Sakakura T., Old L.J., Obata Y. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2994-2999.
31. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., Roskams T., et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11:119-132.
32. Inokuchi S., Aoyama T., Miura K., Osterreicher C.H., Kodama Y., Miyai K., Akira S., et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:844-849.
33. Bettermann K., Vucur M., Haybaeck J., Koppe C., Janssen J., Heymann F., Weber A., et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 2010, 17:481-496.
34. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
35. Haybaeck J., Zeller N., Wolf M.J., Weber A., Wagner U., Kurrer M.O., Bremer J., et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009, 16:295-308.
36. Nikolaou K., Tsagaratou A., Eftychi C., Kollias G., Mosialos G., Talianidis I. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 2012, 21:738-750.
37. Wong C.M., Kai A.K., Tsang F.H., Ng I.O. Regulation of hepatocarcinogenesis by microRNAs. Front Biosci. (Elite Ed) 2013, 5:49-60.
38. Zhang Y., Wei W., Cheng N., Wang K., Li B., Jiang X., Sun S. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012, 56:1631-1640.
39. Hatziapostolou M., Polytarchou C., Aggelidou E., Drakaki A., Poultsides George A., Jaeger Savina A., Ogata H., et al. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011, 147:1233-1247.
40. Yang X., Liang L., Zhang X.F., Jia H.L., Qin Y., Zhu X.C., Gao X.M., et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 2013, 58:158-170.
41. Zhang Y., Zhang B., Zhang A., Li X., Liu J., Zhao J., Zhao Y., et al. IL-6 upregulation contributes to the reduction of miR-26a expression in hepatocellular carcinoma cells. Braz. J. Med. Biol. Res. 2013, 46:32-38.
42. Kong X., Feng D., Wang H., Hong F., Bertola A., Wang F.-S., Gao B. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012, 56:1150-1159.
43. Furuta M., Kozaki K.I., Tanaka S., Arii S., Imoto I., Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31:766-776.
44. Consortium U.I.G., Barrett J.C., Lee J.C., Lees C.W., Prescott N.J., Anderson C.A., Phillips A., et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat. Genet. 2009, 41:1330-1334.
45. Soresi M., Giannitrapani L., D'Antona F., Florena A.M., La Spada E., Terranova A., Cervello M., et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J. Gastroenterol. 2006, 12:2563-2568.
46. He G., Dhar D., Nakagawa H., Font-Burgada J., Ogata H., Jiang Y., Shalapour S., et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 2013, 155:384-396.
47. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
48. Stumhofer J.S., Tait E.D., Quinn W.J., Hosken N., Spudy B., Goenka R., Fielding C.A., et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat. Immunol. 2010, 11:1119-1126.
49. Dibra D., Cutrera J., Xia X., Kallakury B., Mishra L., Li S. Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology 2012, 55:1204-1214.
50. Ding J., Huang S., Wang Y., Tian Q., Zha R., Shi H., Wang Q., et al. Genome-wide screening reveals that miR-195 targets the TNF-alpha/NF-kappaB pathway by down-regulating IkappaB kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology 2013, 58:654-666.
51. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1563-1568.
52. Horie Y., Suzuki A., Kataoka E., Sasaki T., Hamada K., Sasaki J., Mizuno K., et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 2004, 113:1774-1783.
53. He L., Hou X., Kanel G., Zeng N., Galicia V., Wang Y., Yang J., et al. The critical role of AKT2 in hepatic steatosis induced by PTEN loss. Am. J. Pathol. 2010, 176:2302-2308.
54. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
55. Vinciguerra M., Sgroi A., Veyrat-Durebex C., Rubbia-Brandt L., Buhler L.H., Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009, 49:1176-1184.
56. Wu K., Ding J., Chen C., Sun W., Ning B.F., Wen W., Huang L., et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 2012, 56:2255-2267.
57. Poliseno L., Salmena L., Riccardi L., Fornari A., Song M.S., Hobbs R.M., Sportoletti P., et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci. Signal. 2010, 3:ra29.
58. Tumaneng K., Schlegelmilch K., Russell R.C., Yimlamai D., Basnet H., Mahadevan N., Fitamant J., et al. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat. Cell Biol. 2012, 14:1322-1329.
59. Anson M., Crain-Denoyelle A.M., Baud V., Chereau F., Gougelet A., Terris B., Yamagoe S., et al. Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J. Clin. Invest. 2012, 122:586-599.
60. Oguma K., Oshima H., Aoki M., Uchio R., Naka K., Nakamura S., Hirao A., et al. Activated macrophages promote Wnt signalling through tumour necrosis factorα in gastric tumour cells. EMBO J. 2008, 27:1671-1681.
61. Kodama T., Takehara T., Hikita H., Shimizu S., Shigekawa M., Tsunematsu H., Li W., et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J. Clin. Invest. 2011, 121:3343-3356.
62. Lujambio A., Akkari L., Simon J., Grace D., Tschaharganeh D.F., Bolden J.E., Zhao Z., et al. Non-cell-autonomous tumor suppression by p53. Cell 2013, 153:449-460.
63. Bard-Chapeau E.A., Li S., Ding J., Zhang S.S., Zhu H.H., Princen F., Fang D.D., et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011, 19:629-639.
64. Broitman S.A., Gottlieb L.S., Zamcheck N. Influence of neomycin and ingested endotoxin in the pathogenesis of choline deficiency cirrhosis in the adult rat. J. Exp. Med. 1964, 119:633-642.
65. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., Schwabe R.F. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007, 13:1324-1332.
66. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., Caviglia J.M., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
67. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 2010, 39:493-506.
68. Lowenfels A.B., Maisonneuve P., Cavallini G., Ammann R.W., Lankisch P.G., Andersen J.R., Dimagno E.P., et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 1993, 328:1433-1437.
69. Cutrera J., Dibra D., Xia X., Hasan A., Reed S., Li S. Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy. Mol. Ther. 2011, 19:1468-1477.
70. Guerra C., Collado M., Navas C., Schuhmacher A.J., Hernandez-Porras I., Canamero M., Rodriguez-Justo M., et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011, 19:728-739.
71. Lee K.E., Bar-Sagi D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 2010, 18:448-458.
72. di Magliano M.P., Logsdon C.D. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013, 144:1220-1229.
73. Huang H., Daniluk J., Liu Y., Chu J., Li Z., Ji B., Logsdon C.D. Oncogenic K-Ras requires activation for enhanced activity. Oncogene 2014, 33:532-535.
74. Daniluk J., Liu Y., Deng D., Chu J., Huang H., Gaiser S., Cruz-Monserrate Z., et al. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J. Clin. Invest. 2012, 122:1519-1528.
75. Ardito C.M., Gruner B.M., Takeuchi K.K., Lubeseder-Martellato C., Teichmann N., Mazur P.K., Delgiorno K.E., et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22:304-317.
76. Collins M.A., Bednar F., Zhang Y., Brisset J.C., Galban S., Galban C.J., Rakshit S., et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 2012, 122:639-653.
77. Charo C., Holla V., Arumugam T., Hwang R., Yang P., Dubois R.N., Menter D.G., et al. Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor. Pancreas 2013, 42:467-474.
78. Pylayeva-Gupta Y., Lee Kyoung E., Hajdu Cristina H., Miller G., Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012, 21:836-847.
79. Ling J., Kang Y., Zhao R., Xia Q., Lee D.F., Chang Z., Li J., et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:105-120.
80. Cutrera J., Dibra D., Satelli A., Xia X., Li S. Intricacies for posttranslational tumor-targeted cytokine gene therapy. Mediators Inflamm. 2013, 2013:378971.